Unknown

Dataset Information

0

Pharmacokinetics and pharmacodynamics of ?-hydroxybutyrate in healthy subjects.


ABSTRACT: AIMS:?-Hydroxybutyrate (GHB) is used as a treatment for narcolepsy and alcohol withdrawal and as a recreational substance. Nevertheless, there are limited data on the pharmacokinetics and pharmacokinetic-pharmacodynamic relationships of GHB in humans. We characterized the pharmacokinetic profile and exposure-psychotropic effect relationship of GHB in humans. METHODS:Two oral doses of GHB (25 and 35 mg kg(-1) ) were administered to 32 healthy male subjects (16 for each dose) using a randomized, placebo-controlled, cross-over design. RESULTS:Maximal concentrations of GHB were (geometric mean and 95% CI): 218 (176-270) nmol ml(-1) and 453 (374-549) nmol ml(-1) for the 25 and 35 mg kg(-1) GHB doses, respectively. The elimination half-lives (mean ± SD) were 36 ± 9 and 39 ± 7 min and the AUC? values (geometric mean and 95% CI) were 15 747 (12 854-19 290) and 40 113 (33 093-48 622) nmol?min ml(-1) for the 20 and 35 mg kg(-1) GHB doses, respectively. Thus, plasma GHB exposure (AUC0-? ) rose disproportionally (+40%) with the higher dose. ?-Hydroxybutyrate produced mixed stimulant-sedative effects, with a dose-dependent increase in sedation and dizziness. It did not alter heart rate or blood pressure. A close relationship between plasma GHB exposure and its psychotropic effects was found, with higher GHB concentrations associated with higher subjective stimulation, sedation, and dizziness. No clockwise hysteresis was observed in the GHB concentration effect plot over time (i.e., no acute pharmacological tolerance). CONCLUSION:Evidence was found of a nonlinear dose-exposure relationship (i.e., no dose proportionality) at moderate doses of GHB. The effects of GHB on consciousness were closely linked to its plasma exposure and exhibited no acute tolerance.

SUBMITTER: Liechti ME 

PROVIDER: S-EPMC4834605 | biostudies-literature | 2016 May

REPOSITORIES: biostudies-literature

altmetric image

Publications

Pharmacokinetics and pharmacodynamics of γ-hydroxybutyrate in healthy subjects.

Liechti Matthias E ME   Quednow Boris B BB   Liakoni Evangelia E   Dornbierer Dario D   von Rotz Robin R   Gachet Maria Salomé MS   Gertsch Jürg J   Seifritz Erich E   Bosch Oliver G OG  

British journal of clinical pharmacology 20160225 5


<h4>Aims</h4>γ-Hydroxybutyrate (GHB) is used as a treatment for narcolepsy and alcohol withdrawal and as a recreational substance. Nevertheless, there are limited data on the pharmacokinetics and pharmacokinetic-pharmacodynamic relationships of GHB in humans. We characterized the pharmacokinetic profile and exposure-psychotropic effect relationship of GHB in humans.<h4>Methods</h4>Two oral doses of GHB (25 and 35 mg kg(-1) ) were administered to 32 healthy male subjects (16 for each dose) using  ...[more]

Similar Datasets

| S-EPMC5591798 | biostudies-literature
| S-EPMC7496261 | biostudies-literature
| S-EPMC4744690 | biostudies-literature
| S-EPMC8359436 | biostudies-literature
| S-EPMC8453901 | biostudies-literature
| S-EPMC4256622 | biostudies-literature
| S-EPMC5594082 | biostudies-literature
| S-EPMC5117885 | biostudies-literature
| S-EPMC7181426 | biostudies-literature
| S-EPMC6106189 | biostudies-literature